Displaying 1–25 of 8032 results for
Celgene has entered into a global strategic collaboration with Kyn Therapeutics, a Boston-based clinical-stage biotech, to develop immuno-oncology therapies.
The Israel Tax Authority intends to demand that Teva Pharma hands over NIS $1 billion ($271 million) in retroactive tax for 2014-2015, according to sources connected to an Israeli financial publication.
In the coming year, several drugs that treat a range of diseases will far surpass the $1 billion blockbuster mark and continue to grow.
Amid restructuring efforts related to its $63 billion acquisition of Monsanto, Bayer has decided to shutter a facility outside of Pittsburgh.
As the government shutdown drags on, the clock is ticking on the FDA’s ability to process drug approval applications.
About 100 of the returning staff will be concentrating on inspections of high-risk medical device manufacturing facilities, about 70 focused on inspections of high-risk drug manufacturing facilities and about 90 focused on inspections of high-risk biological manufacturing facilities
Voyager Therapeutics appoints Omar Khwaja as its chief medical officer, leaving a post at Roche as global head of neuroscience translational medicine and global head of rare diseases
How innovative EBR solutions are making it easier to scrap paper-based processes
Allergan announced it will establish an R&D presence in the Kendall Square section of Cambridge, Massachusetts.
AstraZeneca's chief medical officer, Sean Bohen is leaving after less than four years at the company, amid the drugmaker's newly announced overhaul.
Health officials in China announced this week that they are investigating why 145 babies were given expired polio vaccines earlier this month.
As political pressure mounts to combat drug costs, a House Oversight Committee has announced that it will probe the pricing policies of 12 major companies.
Johnson & Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto.
In the process of working with the FDA? Expect delays.
AstraZeneca will be closing two manufacturing sites in Colorado in order to consolidate its biologics manufacturing network in one large-scale drug substance facility.
Britain's National Institute for Health and Care Excellence (NICE) rejected Novartis’s migraine drug, Aimovig, concluding that the drug was not a cost-effective use of resources.
The FDA has followed up a Form 483 to Akron Inc. with a warning letter.
Pfizer has decided to call “time of death” on two Indian plants the company took over after its acquisition of Hospira in 2015.
New WalletHub analysis ranks 2019’s Best & Worst Metro Areas for STEM Professionals
Sage Therapeutics reported positive results this week from a trial for a new type of antidepressant.
Merck & Co. could be close to winning a Supreme Court case that could set an important precedent for future product liability claims.
The drugmaker currently employs 1,400 workers at the plant in Eastern France.
While the Takeda is seeing pressure to improve finances, chief executive Christophe Weber said that a sale of its OTC business is not a current priority.
AstraZeneca has appointed well-known but controversial cancer doctor, José Baselga, to head research and development for oncology, as part of a larger overhaul designed to speed drugs to market